TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1347582

Group type: EXPERIMENTAL
Intervention: Thirst-guided drinking
Number of subjects: 8

Group type: COMPARATOR
Intervention: Forced drinking (chilled water every 15-20 min)
Number of subjects: 8
Study: 3899771

Group type: EXPERIMENTAL
Intervention: Sustained-release clomipramine (Anafranil SR) 75 mg once daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional formulation of clomipramine (Anafranil) 75 mg once daily
Number of subjects: 46
Study: 31357225

Group type: EXPERIMENTAL
Intervention: Chairside digital workflow with monolithic lithium disilicate (LS2) crowns
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hybrid digital workflow with CAD/CAM-fabricated zirconia superstructures and hand-layered ceramic veneering crowns
Number of subjects: 33
Study: 30166228

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Docetaxel (Arm A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Gemcitabine (Arm B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 12
Study: 27329547

Group type: EXPERIMENTAL
Intervention: Unidirectional barbed suture (V‐Loc 180; Covidien, Mansfield, MA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional suture (Vicryl; Ethicon, Somerville, NJ)
Number of subjects: 40
Study: 24820768

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO) alone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) with H2 receptor antagonist (H2RA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Magnesium oxide (MgO) with proton pump inhibitor (PPI)
Number of subjects: 71
Study: 23106931

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: HCV-positive subjects
Number of subjects: 175

Group type: COMPARATOR
Intervention: HCV-negative subjects
Number of subjects: 175
Study: 20930341

Group type: EXPERIMENTAL
Intervention: Ozone irrigation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chlorhexidine irrigation
Number of subjects: 16
Study: 18931244

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block with negative aspiration for blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block with visualization of local anesthetic spread
Number of subjects: 0
Study: 15975759

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (IPEC) consisting of doxorubicin, 0.1mg/kg and cisplatin, 15 mg/m² per day for 5 consecutive days.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (cytoreduction alone).
Number of subjects: 38
Study: 12416649

Group type: EXPERIMENTAL
Intervention: Zygote transfer
Number of subjects: 386

Group type: COMPARATOR
Intervention: Embryo transfer
Number of subjects: 386
Study: 10469101

Group type: EXPERIMENTAL
Intervention: Combination treatment of pulsed CO2 laser followed by Q-switched alexandrite laser
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pulsed CO2 laser only
Number of subjects: 8
Study: 7563337

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 sterile powder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 sterile solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pediatric sterile solution (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 microgram (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 micrograms
Number of subjects: 0
Study: 2248533

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 29
Study: 6264865

Group type: EXPERIMENTAL
Intervention: 10 micrograms ethinyl estradiol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 micrograms ethinyl estradiol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 60 micrograms ethinyl estradiol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2000 micrograms estriol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1250 micrograms conjugated estrogens
Number of subjects: 14
Study: 31679946

Group type: EXPERIMENTAL
Intervention: Elexacaftor 200 mg orally once daily plus tezacaftor 100 mg orally once daily plus ivacaftor 150 mg orally every 12 h
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Elexacaftor plus tezacaftor plus ivacaftor
Number of subjects: 107

Group type: COMPARATOR
Intervention: Tezacaftor plus ivacaftor
Number of subjects: 107
Study: 27485100

Group type: EXPERIMENTAL
Intervention: CBT + fluoxetine
Number of subjects: 62

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 62

Group type: COMPARATOR
Intervention: CBT + placebo
Number of subjects: 62
Study: 26384639

Group type: EXPERIMENTAL
Intervention: PEM 0.5%, 1%, 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23375165

Group type: EXPERIMENTAL
Intervention: Vaccine A (types 1:2:3 = 3:100:100 DU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine B (types 1:2:3 = 1.5:50:50 DU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine C (types 1:2:3 = 0.75:25:25 DU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP-sIPV (with sIPV antigens)
Number of subjects: 0
Study: 21441782

Group type: EXPERIMENTAL
Intervention: PHiD‐CV (3 doses)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PHiD‐CV (booster)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PHiD‐CV (2-dose catch-up)
Number of subjects: 240

Group type: COMPARATOR
Intervention: HAV (control)
Number of subjects: 240
Study: 19944004

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with no-updosing regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) with traditional updosing approach
Number of subjects: 0
Study: 16816491

Group type: EXPERIMENTAL
Intervention: C. pen and gentamicin intravenously (IV), followed by oral amoxicillin
Number of subjects: 71

Group type: COMPARATOR
Intervention: amox-clav IV, followed by oral amox-clav
Number of subjects: 71
Study: 14594793

Group type: EXPERIMENTAL
Intervention: Intraperitoneal amino acid solution (2 L, 1.1%)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intraperitoneal glucose solution (2.27%)
Number of subjects: 13
Study: 10669270

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with ketobemidone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nurse-controlled analgesia (NCA) with ketobemidone
Number of subjects: 48
Study: 9380790

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (900 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8362600

Group type: EXPERIMENTAL
Intervention: s.c. rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: s.c. rIL-2 in combination with s.c. rIFN-alpha at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week
Number of subjects: 107
Study: 2433307

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (IVGG) plus aspirin (ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (ASA) alone
Number of subjects: 0
Study: 28985310

Group type: EXPERIMENTAL
Intervention: Early mobilisation implementation intervention for staff
Number of subjects: 12490
Study: 26595503

Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage (ENGBD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Endoscopic gallbladder stenting (EGBS)
Number of subjects: 35
Study: 24562873

Group type: EXPERIMENTAL
Intervention: Web-based followup
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual-care (in-person followup)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Preference for followup method
Number of subjects: 229
Study: 24312458

Group type: EXPERIMENTAL
Intervention: Early IUGR
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Late IUGR (VD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Late IUGR (non-VD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All IUGR subforms
Number of subjects: 102

Group type: COMPARATOR
Intervention: AGA
Number of subjects: 102
Study: 20395260

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) Q5 (>5.1-6.9 mmol/L)
Number of subjects: 6447

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) Q5e (5.8-6.9 mmol/L)
Number of subjects: 6447
Study: 18962988

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15478314

Group type: EXPERIMENTAL
Intervention: Oral E2 valerate 2-4 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal E2 50-100 microg/day
Number of subjects: 20
Study: 11487675

Group type: EXPERIMENTAL
Intervention: Alteplase (2 mg per 2 mL)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 9777425

Group type: EXPERIMENTAL
Intervention: Intramuscular cyanocobalamin injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 50
Study: 7828216

Group type: EXPERIMENTAL
Intervention: Lateral chest wall temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Axillary temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal temperature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitting (activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standing or walking (activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercising (activity)
Number of subjects: 0
Study: 3046651

Group type: EXPERIMENTAL
Intervention: Pre-operative prophylactic dose of a combination of crystalline penicillin and chloramphenicol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 30341773

Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP crème applied three times daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo crème without CPP-ACP
Number of subjects: 24
Study: 27849566

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 400 mg once daily for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Valsartan 320 mg once daily for 4 weeks
Number of subjects: 72
Study: 26306691

Group type: EXPERIMENTAL
Intervention: Patient-centered systematic drug review intervention by trained primary care physicians (PCPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving a lecture on multimorbidity and instructions for usual care
Number of subjects: 0
Study: 23777957

Group type: EXPERIMENTAL
Intervention: Heavy-resistance training exercise of knee extension (five sets of eight repetitions with 80% of one-repetition maximum, three sessions a week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 21227601

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Client motivation at the beginning of the session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Days of use during treatment
Number of subjects: 0
Study: 18382901

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (Aerodiol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16480471

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 30 mg/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 20 mg/ml with 5 microg/ml epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study: 12900689

Group type: EXPERIMENTAL
Intervention: 5 mg x kg‐1 of caffeine in the AM and 2.5 mg x kg‐1 of caffeine in the PM (trial A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 mg x kg‐1 of caffeine in the AM and placebo in the PM (trial C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo in both AM and PM (trial B)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Placebo in the AM and 5 mg x kg‐1 of caffeine in the PM (trial D)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo in the AM and placebo in the PM (trial B)
Number of subjects: 9
Study: 11180196

Group type: EXPERIMENTAL
Intervention: Uroxin (400 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Noroxin (400 mg)
Number of subjects: 18
Study: 9420044

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole (200 mg) administered as four 1-hour infusions on days 1-2, followed by daily 1-hour infusions of 200 mg from days 3-7.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg once daily) after i.v. treatment.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg twice daily) after i.v. treatment.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous treatment phase compared to oral treatment phase.
Number of subjects: 16
Study: 8237748

Group type: EXPERIMENTAL
Intervention: Theophylline (aminophylline, mean concentration 16.1 mg/L)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3698783

Group type: EXPERIMENTAL
Intervention: Home teaching
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control (no home teaching)
Number of subjects: 393
Study: 31330767

Group type: EXPERIMENTAL
Intervention: Mentha longifolia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Urtica dioica
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Viola odorata
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29033381

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg intravenous infusion once yearly for 2 years
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 27600465

Group type: EXPERIMENTAL
Intervention: TIMI flow grade ≤1 before PCI
Number of subjects: 738
Study: 24866597

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging guided in‐bore biopsy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard systematic transrectal ultrasound guided biopsy
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination of both methods
Number of subjects: 132
Study: 22621776

Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 80 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 320 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orally inhaled BDP HFA 320 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intranasal BDP HFA 320 μg vs Orally inhaled BDP HFA 320 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal BDP HFA 80 μg vs 320 μg
Number of subjects: 30
Study: 19880495

Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes (CTLs) prophylaxis
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: EBV-specific cytotoxic T lymphocytes (CTLs) treatment
Number of subjects: 114
Study: 17655686

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/10-, 10/20-, 10/40-, or 10/80-mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SIMVA 10-, 20-, 40-, or 80-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA
Number of subjects: 0
Study: 15131430

Group type: EXPERIMENTAL
Intervention: Closed wound suction drain
Number of subjects: 83

Group type: COMPARATOR
Intervention: No closed wound suction drain
Number of subjects: 83
Study: 12235450

Group type: EXPERIMENTAL
Intervention: Atovaquone (250 mg daily) plus chloroguanide (100 mg daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 119
Study: 9828753

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study: 8205446

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Prepacol
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 163
Study: 2686421

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg IV every 12 hours followed by 500 mg orally every 12 hours)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ceftazidime (2 g IV every 8 to 12 hours)
Number of subjects: 47
Study: 30679301

Group type: EXPERIMENTAL
Intervention: Guided imagery and progressive muscle relaxation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 208
Study: 28925467

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 120
Study: 26311325

Group type: EXPERIMENTAL
Intervention: SMS reminders for each dose of medicine in addition to the standard of care.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care as per institutional guidelines.
Number of subjects: 200
Study: 24146460

Group type: EXPERIMENTAL
Intervention: Sophora flower formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21546500

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride plus low-dose interleukin-2
Number of subjects: 320

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 320
Study: 18192453

Group type: EXPERIMENTAL
Intervention: Chromoscopic endomicroscopy with targeted biopsies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pan-colonic chromoscopy assisted colonoscopy
Number of subjects: 0
Study: 16950752

Group type: EXPERIMENTAL
Intervention: rhGH (0.4 mg/day for males, 0.6 mg/day for females) for 12 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control values from fourteen healthy subjects matched by age, sex, and BMI
Number of subjects: 21
Study: 14597992

Group type: EXPERIMENTAL
Intervention: Postoperative ultrasound screening for proximal and distal thrombosis
Number of subjects: 346

Group type: COMPARATOR
Intervention: Prolonged prophylaxis with LMWH
Number of subjects: 346
Study: 16841668

Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC) high-dose 160 mg, 3 times per day for 14 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC) low-dose 80 mg, 3 times per day for 14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Domperidone 10 mg, 3 times per day for 14 days (Control group)
Number of subjects: 90
Study: 10472523

Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 9
Study: 8735998

Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise (n = 18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Videotape watching (n = 16)
Number of subjects: 34
Study: 1836918

Group type: EXPERIMENTAL
Intervention: 2 micrograms intradermal injection
Number of subjects: 425

Group type: COMPARATOR
Intervention: 20 micrograms intramuscular injection
Number of subjects: 425
Study: 6120717

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5, 1.0, and 2.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Camazepam (10-20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31647535

Group type: EXPERIMENTAL
Intervention: mini‐AVR
Number of subjects: 5801

Group type: COMPARATOR
Intervention: AVR
Number of subjects: 5801
Study: 27817985

Group type: EXPERIMENTAL
Intervention: Spacer fabric
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cotton fabric
Number of subjects: 6
Study: 25468682

Group type: EXPERIMENTAL
Intervention: Methylphenidate (1 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24699217

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) with positive end-expiratory pressure (PEEP)
Number of subjects: 24
Study: 23127528

Group type: EXPERIMENTAL
Intervention: Monitoring of serum CA19-9
Number of subjects: 90
Study: 20214327

Group type: EXPERIMENTAL
Intervention: YHF + Omeprazole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 46
Study: 18085908

Group type: EXPERIMENTAL
Intervention: Familias Unidas + PATH
Number of subjects: 266
Study: 15000770

Group type: EXPERIMENTAL
Intervention: Innovo insulin doser
Number of subjects: 217

Group type: COMPARATOR
Intervention: NovoPen 3
Number of subjects: 217
Study: 11133319

Group type: EXPERIMENTAL
Intervention: Young adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both age groups
Number of subjects: 0
Study: 9880943

Group type: EXPERIMENTAL
Intervention: albendazole sulphoxide in lipidic matrix of Gelucire 44/14 (ABZSLM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: albendazole (ABZLM)
Number of subjects: 8
Study: 7972311

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml at 0, 2, 4, 8 and 12 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (diltiazem 120 mg orally without grapefruit juice)
Number of subjects: 9
Study: 2657428

Group type: EXPERIMENTAL
Intervention: Prednisone, 0.75 mg/kg/day (n = 33)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Prednisone, 1.5 mg/kg/day (n = 34)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: High-dose prednisone (1.5 mg/kg/day)
Number of subjects: 103
Study: 30726692

Group type: EXPERIMENTAL
Intervention: Omadacycline (100 mg intravenously every 12 hours for two doses, then 100 mg intravenously every 24 hours; transition to oral 300 mg every 24 hours after 3 days)
Number of subjects: 774

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg intravenously every 24 hours; transition to oral 400 mg every 24 hours after 3 days)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 774

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 774
Study: 29102674

Group type: EXPERIMENTAL
Intervention: Ologen (biodegradable collagen matrix)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional surgery (control)
Number of subjects: 14
Study: 26482031

Group type: EXPERIMENTAL
Intervention: Negative-pressure incision therapy device applied for 5-7 days
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 340